Sorafenib and Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Brian Leber, MD, FRCPC
McMaster Children's Hospital at Hamilton Health Sciences
Study Chair - David A. MacDonald, MD
Nova Scotia Cancer Centre
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Qeii Health Sciences Center
Halifax, Nova Scotia, Canada
- Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, Canada
- Univ. Health Network-Princess Margaret Hospital
Toronto, Ontario, Canada
- Mcgill University - Dept. Oncology
Montreal, Quebec, Canada
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 27 Nov 2007
- Primary completion
- 18 Mar 2010
- Completion
- 10 Jan 2013
- Last update posted
- 4 Aug 2023
- Registered enrollment
- 21
- Registry id
- NCT00516828
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.